概述
-
货号
FHC08010
-
种属反应性
Human -
宿主
Human -
同种型
IgG1 -
克隆类型
Monoclonal -
偶联物
Unconjugated -
靶标
HLA-DR antigens-associated invariant chain, HLA class II histocompatibility antigen gamma chain, CD74, CLIP, Ia antigen-associated invariant chain, DHLAG, Ii -
浓度
1 mg/ml -
内毒素水平
Please contact with the lab for this information. -
纯度
>95% as determined by SDS-PAGE. -
纯化方式
Protein A/G purified from cell culture supernatant. -
Accession号
P04233 -
克隆号
SP7219
-
应用
FCM -
状态
Liquid -
保存溶液
0.01M PBS, pH 7.4. -
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
图片
参考文献
- Discovery and preclinical development of novel CD74-targeting antibody-drug conjugates (ADCs) with significant activity in multiple myeloma (MM) cell lines …
- High Frequency of CD74 Expression in B-Cell Non-Hodgkin's Lymphoma (NHL) and Targeting with SΤRO-001, a Novel Anti-CD74 Antibody Drug Conjugate …
- CD74 Is expressed in relapsed and refractory multiple myeloma and can be targeted with a novel anti-CD74 antibody drug conjugate, SΤRO-001
- High frequency of CD74 expression in lymphomas: implications for targeted therapy using a novel anti‐CD74‐drug conjugate
- Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001
- Characterization and preclinical development of STRO-001, a novel CD74-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies
- Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001
- Targeting CD74 with novel antibody drug conjugates (ADCs) for the treatment of B-cell non-Hodgkin's lymphoma (NHL)
- Nonclinical safety evaluation of STRO-001, a site-specific anti-CD74 antibody-drug conjugate for the potential treatment of B-cell malignancies
- Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia
评价
